Vidofludimus

Vidofludimus is an orally active inhibitor for dihydroorotate dehydrogenase (DHODH) and also is a novel modulator for farnesoid X receptor (FXR). Vidofludimus, as an immunomodulatory agent, can be used for the research of autoimmune disorders such as inflammatory bowel disease (IBD). Vidofludimus also can be used for the research of fatty liver by targeting FXR^[1][2][3]. IC50 & Target:EC50: 450 nM (FXR)^[1]
IC50: 160 nM (human DHODH)^[3] In Vitro:Vidofludimus (0-1 µM) selectively activats FXR in a concentration dependent manner with an EC₅₀ value of about 450 nM in inducing the recruitment of various coactivator LXXLL motifs^[1].
Vidofludimus (0-8 μM) blocks nuclear translocation of p65 by suppressing IKK-IκB-NF-κB pathway^[1].
Vidofludimus has inhibitory activity for human DHODH with an IC₅₀ value of 160 nM^[2].
Vidofludimus inhibits dihydro-orotate dehydrogenase and lymphocyte proliferation in vitro^[3].
Vidofludimus inhibits interleukin (IL)-17 secretion in vitro independently of effects on lymphocyte proliferation^[3].
Vidofludimus completely blocks IL-23 + IL-1β-stimulated secretion of IL-17 by colonic strips in ex vivo^[3]. In Vivo:Vidofludimus (i.p.; once daily; for 14 days) exerts effects on dextran sodium sulfate (DSS) induced colitis in an FXR-dependent manner in vivo^[1].
Vidofludimus (p.o; 60 mg/kg; for 6 days) effectively improves many parameters of TNBS-induced colitis in rats and has inhibitory effects on colonic STAT3 and IL-17^[3].